Retroviral Matrix Proteins: A Structural Perspective  by Conte, Maria R. & Matthews, Stephen
MINIREVIEW
Retroviral Matrix Proteins: A Structural Perspective
Maria R. Conte and Stephen Matthews1
Department of Biochemistry, Imperial College of Science, Technology and Medicine, Exhibition Road,
South Kensington, London SW7 2AY, United Kingdom
Received January 14, 1998; returned to author for revision March 17, 1998; accepted April 22, 1998
INTRODUCTION
Retroviral assembly is a crucial process in the late
stage of the virus life cycle, based on the ability of the
Gag proteins to direct the formation of virion-like parti-
cles (for reviews see Wills and Craven, 1991; Hunter,
1994). The Gag polyprotein is the major structural com-
ponent of retroviruses which, after inducing the release
of nascent particles, is proteolytically cleaved into sev-
eral smaller proteins by the viral protease (PR). While the
size, the sequence, and the protein content of the Gag
protein precursor vary dramatically, all retroviruses con-
tain three principal mature Gag proteins, the matrix (MA),
the capsid (CA), and the nucleocapsid (NC). Despite
many differences, it is possible to identify only two types
of Gag proteins, according to the pathway followed dur-
ing the viral morphogenesis process (for reviews see
Wills and Craven, 1991; Hunter, 1994). In most retrovi-
ruses (lentiviruses and mammalian and avian retrovi-
ruses), known as type C, the Gag polyproteins are effi-
ciently targeted to the plasma membrane, where particle
formation and budding occur simultaneously. The Gag
protein precursors of the second morphogenic type as-
semble in the cytoplasm to form a core particle which is
then transported to the plasma membrane and released.
The best characterized viruses of the latter class are the
Mason-Pfizer monkey virus (M-PMV) and the mouse
mammary tumor virus (MMTV), which have been desig-
nated type D and type B retroviruses, respectively (for
reviews see Wills and Craven, 1991; Hunter, 1994). Sev-
eral investigations have been carried out in order to
achieve a detailed and clear picture of the complex
Gag-mediated assembly process, but still the exact role
of the Gag proteins as well as the molecular basis of viral
protein–cell protein interactions are not fully understood.
In mature virions, the amino terminal matrix protein of
the gag gene product has been found to be a component
of the envelope-associated capsid, which lines the inner
surface of the virus envelope and is associated with the
viral membrane (Gelderblom et al., 1987). Mutagenesis
and specific in-frame deletions within matrix proteins
(MAs) of several retroviruses have provided information
about their key role in Gag stability, capsid assembly,
transport, and budding. Recently the three-dimensional
structures of several matrix proteins have been deter-
mined, providing an interesting insight into retroviral
morphology. In this review, the characteristics and prop-
erties of retroviral matrix proteins are examined and,
where possible, analyzed at the atomic level.
ROLES AND PROPERTIES OF MATRIX PROTEINS
Comparisons of retroviral matrix protein structures
The three-dimensional structures of five retroviral MAs
have been determined (Fig. 1). These include MAs from
human immunodeficiency virus type 1 (HIV-1) (Matthews
et al., 1994, 1995; Massiah et al., 1994), bovine leukemia
virus (BLV) (Matthews et al., 1996), human T-cell leuke-
mia virus type II (HTLV-II) (Christensen et al., 1996), and
M-PMV (Conte et al., 1997) by nuclear magnetic reso-
nance (NMR). In addition, the solution structure of the
bioactive membrane targeting and binding domain (M) of
the Rous sarcoma virus (RSV) MA has been recently
determined (McDonnell et al., 1998) (Fig. 1). The HIV-1
(Hill et al., 1996) and simian immunodeficiency virus (SIV)
(Rao et al., 1996) MA structures have been resolved by
X-ray crystallography. Although these structures agree
well with their NMR counterparts they have revealed
additional clues regarding MA organization. In both crys-
tal structures, MAs are arranged around a crystallo-
graphic three-fold axis producing a trimer.
The structures are predominantly composed of a-he-
lices which are closely packed and joined by loops or
regions of extended structure. The topology of the first
four a-helices of HIV-1 and SIV MAs displays a striking
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similarity with those of BLV MA, HTLV-II MA, M-PMV MA,
and RSV M protein. The 3–10 helices at 49–52 in HIV-1
and SIV MA also align well with 3–10 helices at 57–61 in
HTLV-II MA, at 41–45 in M-PMV MA, and at 43–46 in RSV
M. In addition, all the MAs and the RSV M present the
majority of their basic side chains on one side of the
molecule. Despite the structural similarities, there are
also some notable differences. First, the b-sheet region
of HIV-1 and SIV MAs is not seen in the rest. Second, an
additional a-helix is observed at the C-terminus of HIV-1
and SIV. Third, the N-terminal helix is oriented at a
different angle with respect to the rest of the molecules
in each of the structures.
MA self-association and organization
MAs have been shown to actively participate in the
viral capsid assembly and stability. The production of
virus-like particles from baculovirus expression of SIV
MA indicates that MA contains determinants of self-
association (Gonzalez et al., 1993). Using electron mi-
croscopy a locally ordered shell-like structure has been
visualized immediately beneath the viral envelope of
retroviruses (Gelderblom et al., 1989; Nermut et al., 1994;
Fuller et al., 1997). Furthermore, X-ray crystallography
has revealed a trimeric assembly intermediate for SIV
and HIV MA and also a plausible model for higher order
organization within the mature viral matrix (Hill et al.,
1996; Rao et al., 1995) (Fig. 2). The topological similarity
within MA structures enables similar models to be ex-
tended to BLV, HTLV, M-PMV, and RSV. Some evidence
for the validity of these models has been provided by
mutagenesis studies, in which amino acid changes at
the proposed trimer interface of HIV-1 (residues 64, 70,
74) and M-PMV (residues 43, 72) MAs result in inefficient
capsid assembly (Cannon et al., 1997; Conte et al., 1997;
Morikawa et al., 1995; Rhee and Hunter, 1991). Upon
trimer formation only a small surface area is buried,
which is consistent with MAs being predominantly mo-
nomeric in solution (Matthews et al., 1994, 1995, 1996;
Massiah et al., 1994; Christensen et al., 1996; Conte et
al., 1997; McDonnell et al., 1998). The additional driving
force necessary for complete virion assembly may be
provided by oligomerization of capsid protein (Dorfman
et al., 1994a; Momany et al., 1996; Gamble et al., 1997).
Membrane binding
The membrane binding domain of most retroviral Gag
proteins has been mapped to the myristoylated N-termi-
nal region (Cannon et al., 1997; Jorgensen et al., 1992;
Soneoka et al., 1997; Verderame et al., 1996; Wills et al.,
1991; Zhou et al., 1994). Despite little sequence homology
amongst MAs the most common feature is the cotrans-
lational addition of myristic acid to the N-terminal gly-
cine. In viruses carrying the myristoylated MA, the my-
ristate moiety appears to play a key role in the mem-
brane binding of the Gag precursor protein, and mutation
of the N-terminal Gly residue blocks particle assembly in
HIV-1, murine leukemia virus (MuLV), and spleen necro-
sis virus (Bryant and Ratner, 1990; Freed et al., 1994;
Gottlinger et al., 1991; Jorgensen et al., 1988; Mergener et
al., 1992; Ono et al., 1997; Schultz and Rein, 1989). There
are however, some retroviruses, including RSV, visna
virus, equine infectious anemia virus (EIAV), and caprine
arthritis-encephalitis virus (CAEV), that replicate without
the need of myristoylation (Henderson et al., 1987;
Palmiter et al., 1978; Towler et al., 1988; Wilk et al., 1992).
FIG. 1. MOLSCRIPT diagram (Kraulis, 1991) representing the back-
bone trace for the representative structures for HIV-1 MA, SIV MA,
HTLV-II MA, BLV MA, M-PMV MA, and RSV M. The N-termini are
labeled.
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In RSV MA the 87 N-terminal amino acid region has been
mapped as a membrane targeting and binding domain
(M domain) (Wills et al., 1991; Verderame et al., 1996;
Nelle and Wills, 1996; McDonnell et al., 1998). The struc-
tural similarity of the M domain of RSV MA (McDonnell et
al., 1998) to the other MAs suggests that the mechanism
for the membrane targeting and binding process of the
nonmyristoylated MAs contains features in common with
that of myristoylated MAs.
In vivo and in vitro studies of mutant MAs and recently
the structural studies have provided detailed information
regarding the membrane binding domain (Cannon et al.,
1997; Christensen et al., 1996; Conte et al., 1997; Hill et
al., 1996; Massiah et al., 1994; Matthews et al., 1994,
1995, 1996; McDonnell et al., 1998; Rao et al., 1995;
Soneoka et al., 1997; Spearman et al., 1997; Verderame et
al., 1996; Wills et al., 1991; Zhou et al., 1994; Zhou and
Resh, 1996). In HIV-1 and SIV, this motif is formed by the
numerous arginine and lysine residues within the N-
terminal 32 amino acids. In particular, this stretch of
basic amino acids (residues 15–32), which are located at
the end of the first a-helix, within the first two b-strands
and at the beginning of the second a-helix, forms an
extensive basic surface exposed to the solvent. In BLV
MA, HTLV MA, M-PMV MA, and RSV M the majority of
basic residues are not concentrated at the N-terminus,
but still fall on one side of the molecule within the 3D
structure. In addition, all the basic residues, which have
been implicated in membrane targeting and binding,
project from the upper surface of the trimers (Fig. 2).
These are ideally situated for the interaction with acidic
phospholipid heads and the N-terminal myristate group
is proximally positioned for burial in the membrane. The
similarity of the membrane interacting site of M-PMV MA
with that of type C retroviruses suggests that the Gag
transport and binding to the plasma membrane in type C
and D retroviruses is highly related. A second basic
region, not observed in type C retroviral MAs, has been
shown on the lower surface of the M-PMV MA trimer. The
functional significance of this second positively charged
region is unknown, but it has been proposed to interact
with negatively charged M-PMV Gag proteins, namely,
pp24 or p12 (Conte et al., 1997).
It has been proposed that retroviral MA and negative-
strand RNA virus M proteins possess quite similar mem-
brane binding motif and overall three-dimensional struc-
ture (Lenard, 1996). The crystal structure of a bifunctional
membrane–RNA binding protein, the influenza virus ma-
trix protein M1, containing the N-terminal membrane
binding (N) domain and the middle (M) domain, has been
recently resolved (Sha and Luo, 1997). The N domain
contains four a-helices joined by short loops and several
FIG. 2. MOLSCRIPT diagram (Kraulis, 1991) representing the backbone trace for an extended arrangement of trimers for SIV MA. The trimer,
corresponding to the crystal structure, is viewed from the top, i.e., the proposed membrane-interacting surface. CD is plausibly located in the center
of the arrangement.
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exposed basic residues to interact with the membrane.
However, the orientation of the helices with respect to
each other is different from that of retroviral MAs.
Gag transport and nuclear import
Several lines of evidence suggest that domains within
retroviral MAs are involved in virus particle transport
within the host cell and consequently in determining the
retroviral morphogenesis. Myristic acid, where present,
and other determinants in type C MAs have been iden-
tified that are required for Gag transport to the mem-
brane (Cannon et al., 1997; Facke et al., 1993; Gonzalez et
al., 1993; Jorgensen et al., 1988; Soneoka et al., 1997;
Yuan et al., 1993; Zhou et al., 1994). Also, the myristate
group in the type D virus, M-PMV, is not required for
particle formation but is essential for the intracellular
transport of preassembled particles to the plasma mem-
brane (Rhee and Hunter, 1987). There are also M-PMV
MA mutants that are myristoylated but have been shown
to be defective in capsid transport (Rhee and Hunter,
1991). Notably, a single point mutation in the type D
M-PMV MA redirects the Gag assembly from an intracy-
toplasmic site to the plasma membrane, in a manner
similar to that of type C retroviruses (Rhee and Hunter,
1990). This mutation, Arg 55 to Trp, occurs within an
18-amino-acid stretch which is conserved in type D and
type B MAs, and it has been speculated to be a specific
targeting signal to the cytoplasm. This domain encom-
passes the exposed turn centered at residue 49 which
could be available for recognition by a specific intracel-
lular factor to mediate transport (Conte et al., 1997). The
fact that a single point mutation can significantly alter
morphogenesis suggests that the difference between
type C and type D retrovirus capsid assembly is very
subtle. This is supported by the high degree of structural
similarity found for both MA types.
In contrast with most mammalian and avian retrovi-
ruses, HIV and other lentiviruses can infect nonmitotic
cells, such as terminally differentiated macrophages
(Humphries and Temin, 1972, 1974; Weinberg et al., 1991;
Lewis and Emerman, 1994). Viral proteins, namely, MA,
the accessory viral protein R (Vpr), and integrase have
been implicated in the active transport of the viral prein-
tegration complex through the nucleopore and enable
subsequent chromosomal integration in the absence of
mitosis (Bukrinsky et al., 1993, 1992; Heinzinger et al.,
1994; Lewis et al., 1992; von Schwedler et al., 1994;
Gallay et al., 1997). Although a nuclear localization signal
(NLS) has been identified within the positively charged
second strand of HIV-1 and SIV MA (residues 25–33),
present only in lentiviral MA structures (Bukrinsky et al.,
1993; Heinzinger et al., 1994; von Schwedler et al., 1994;
Christensen et al., 1996; Conte et al., 1997; Massiah et al.,
1994; Matthews et al., 1994, 1995, 1996), other data have
failed to support the karyophilic role for MA (Fouchier et
al., 1997). Utilization of three distinct nuclear import as-
says failed to provide direct evidence for HIV-1 MA sup-
plying the NLS that enables HIV-1 to infect nondividing
cells (Fouchier et al., 1997). Moreover, these studies
demonstrated that the double mutation 26KK 2 . TT,
which disrupts the basic region, is equivalently deleteri-
ous to the replication of nondividing and dividing cells,
since it reduces the rate at which the HIV-1 Gag polypro-
tein is processed by the viral protease. In support of the
presence of a NLS signal in MA, it has been proposed
that MA carries out both the nuclear targeting function
and the plasma membrane localization signal. The reg-
ulation of these opposing targeting functions has been
suggested to involve both myristoylation and phosphory-
lation of MA (Bukrinskaya et al., 1996; Gallay et al., 1995a,
b; Spearman et al., 1997; Zhou and Resh, 1996).
According to the hypothesis of a conformational myr-
istoyl switch mechanism (Zhou and Resh, 1996; Spear-
man et al., 1997), the myristic acid has been proposed to
be a key regulator of the Gag–membrane and MA–mem-
brane interaction. This mechanism proposes that mature
HIV-1 MA adopts a conformation different from that of the
MA domain within Gag. The myristate group is exposed
and available for membrane targeting and binding in Gag
but is sequestered by the globular core of MA in the early
postentry events of the virus life cycle. A role for the
myristate group in the intracellular transport has also
been observed in M-PMV. Myristoyl minus M-PMV MA
blocks the intracellular transport of assembled capsids
to the plasma membrane (Rhee and Hunter, 1991).
Several hypotheses involving MA phosphorylation
have also been proposed to influence the subcellular
localization of MA. Bukrinskaya et al. (1996) suggested
that MA serine phosphorylation (in particular S38, S67,
S77, S111) disrupts MA membrane binding in the early
stages of virus life cycle, thus allowing it to translocate to
the nucleus. On the contrary, other studies (Gallay et al.,
1995a, b) proposed that the critical regulator of the MA
nuclear import process is the C-terminal tyrosine (Y132)
phosphorylation of MA during virus maturation. It has
been proposed that this does not stimulate the disruption
of electrostatic interactions between MA and the mem-
brane but the binding of the MA to the integrase, an
essential component of the viral preintegration complex.
However, these results remain controversial at the mo-
ment (Gallay et al., 1995a, b; Freed et al., 1997; Trono and
Gallay, 1997). Moreover, these serine/tyrosine phosphor-
ylation sites, namely, S38, S67, S77, S111 (Bukrinskaya et
al., 1996), and Y132 (Gallay et al., 1995a, b) are distributed
throughout the HIV-1 MA structure and not localized to a
specific region.
Incorporation of viral envelope glycoproteins
Retroviral envelope glycoproteins are incorporated
into the virions during budding of virus particles from the
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plasma membrane of the infected cell. The envelope
glycoprotein complex of replication competent retrovi-
ruses comprises two proteins, one external (SU) and the
other membrane spanning (TM) (for reviews see Hunter,
1994; Wills and Craven, 1991). Both proteins are encoded
by the env gene and are synthesized in the form of a
glycosylated, polyprotein precursor, which is proteolyti-
cally cleaved to its mature proteins within the Golgi
(Hunter, 1994). The intimate association between MA
with the membrane implies that MA forms a specific
interaction with the cytoplasmic domain (CD) of the viral
transmembrane glycoprotein (TM). It is noteworthy to say
that lentiviruses are unique among retroviruses in having
a remarkably long CD, for example the HIV-1 and HIV-2
CD is approximately 150 amino acids (Myers et al., 1993),
the EIAV is 200 (Rice et al., 1990), whereas other type C
and type D retroviruses contain a CD in the range of
20–40 amino acids (Hunter et al., 1983; Pinter and Hon-
nen, 1983; Sonigo et al., 1986).
There are several lines of evidence which support a
direct role for MA in the incorporation of the envelope
glycoproteins. Many single and multiple amino acid sub-
stitutions, which are located in first two N-terminal heli-
ces of HIV-1 MA (for example point mutations L12E,
L30E, V34E), can block envelope incorporation (Dorfman
et al., 1994b; Freed and Martin, 1995, 1996). This region
lies on the perimeter of the trimers (Fig. 2) and may
therefore be proximal to CD within the virion. Interest-
ingly, charged substitutions at position 12 of HIV-1 MA
(L12E, L12R, L12K, and L12D) resulted in loss of detect-
able Env in virion-associated material, whereas neutral
substitutions (L12W, L12Y, L12I, and L13L) significantly
decreased, but did not abolish Env incorporation (Freed
and Martin, 1996). In addition, second-site mutations in
the same region can compensate (Ono et al., 1997). The
V34I change compensates for the Env incorporation de-
fect imposed by MA amino acid 12 mutations, and Q62R
has the same effect for the V34E mutant. Mutations in the
CD from HIV-1 also specifically block Env incorporation
into virions (Dubay et al., 1992; Freed and Martin, 1996;
Yu et al., 1992, 1993). Other retroviral MAs have also been
implicated in Env incorporation. MA and Env chemically
cross-link in RSV (Gebhardt et al., 1984) and changes
within M-PMV MA result in inefficient incorporation
(Rhee and Hunter, 1990) and postbudding cleavage of
Env (Brody et al., 1992).
Evidence also exists contrary to this hypothesis. Ex-
tensive mutations in the RSV (Perez et al., 1987), HIV-1
(Gabuzda et al., 1992; Wilk et al., 1992), SIV (Zingler and
Littman, 1993), and MuLV (Ragheb and Anderson, 1994;
Soneoka et al., 1997) CDs do not block Env incorporation.
Furthermore, envelope proteins with short CDs, trun-
cated CDs, and nonretroviral glycoproteins can be incor-
porated into particles (Freed and Martin, 1995; Hunter,
1994; Johnston et al., 1993; Landau and Littman, 1992;
Lusso et al., 1990a, b; Spector et al., 1990; Young et al.,
1990). This is notably demonstrated by the efficient in-
corporation of MuLV and HTLV-I glycoproteins into HIV-1
(Freed and Martin, 1995; Landau and Littman, 1992;
Lusso et al., 1990a, b; Spector et al., 1990) and by the
introduction of human lymphocyte membrane protein
CD4 into RSV virions (Hunter, 1994; Young et al., 1990).
Despite the inconsistencies, direct evidence for a spe-
cific interaction between the N-terminal region of MA
and the CD in HIV has been recently provided by Cosson
(1996). It is clearly emerging that a distinct behavior
for HIV exists that is related to the unusual large CD
(Freed and Martin, 1995; Mammano et al., 1995, 1997).
Pseudotyping analyses demonstrate that the short and
truncated HIV CDs (Freed and Martin, 1995) are effi-
ciently incorporated into HIV-1 particles bearing MA mu-
tants that block incorporation of full-length Env. HIV Env
is also excluded from Gag particles from visna virus
(Dorfman et al., 1994b) and MuLV (Wilson et al., 1989),
although MuLV can form hybrids with other retroviral
glycoproteins (Landau and Littman, 1992; Vile et al., 1991;
Wilson et al., 1989). Interestingly, visna virus particles
containing HIV-1 MA acquire the ability to incorporate
HIV-1 Env (Dorfman et al., 1994b), and truncation of HIV-1
CD results in improved incorporation into MuLV (Mam-
mano et al., 1997). In the case of the lentiviruses, where
CD is large, a closer and specific association between
CD and the matrix may be required. Furthermore, from
the suggested organization of MA in the mature virion
(Fig. 2) it is plausible that larger CDs would interact more
intimately with MA.
OVERVIEW
Mutagenesis studies carried out on retroviral matrix
proteins have enabled both their properties and roles to
be identified. It is only recently that, with the knowledge
of MA three-dimensional structures, a detailed interpre-
tation of mutagenesis data has been possible. Neverthe-
less analysis of such mutagenesis data is often ham-
pered by the occurrence of mutations that destroy the
global three-dimensional fold rather than disrupt a local-
ized region.
MAs, which likely form trimeric assembly units,
present a positively charged surface and a proximal
myristate group for transport and anchorage to the mem-
brane. The high similarity among MA structures sug-
gests a common mode of assembly, transport, and bind-
ing to the membrane. This also supports the hypothesis
that retroviral morphology is very subtle, such that a
single point mutation is able to change a type D virus to
a type C. In the case of lentiviruses, mutagenesis studies
also suggest that MA, specifically the N-terminal region,
is also crucially involved in envelope incorporation. Key
elements of MA function are still to be resolved. These
include the role of MA in the postentry nuclear import,
the validity of the myristoyl-switch mechanism, the pre-
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cise role of phosphorylated MA, and the involvement of
host transport factors in the assembly process. Rational
mutagenesis, combined with further structural studies,
will help augment the atomic picture of MA function.
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